Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
NCT00106925
Recruiting
This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant. Patients between 10 and 80 years of age who received a donor stem cell transplant at the NIH Clinical Center under an NHLBI protocol may be eligible for this study. Candidates must have had their first transplant at least... Read More
Gender:
ALL
Ages:
Between 7 years and 80 years
Trial Updated:
05/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Graft vs Host Disease, Graft Rejection, Graft-versus-leukemia
Register for Updates
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
NCT04685200
Recruiting
Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease. Researchers want to learn more about this disease. Objective: To understand the biological causes of primary sclerosing cholangitis. Eligibility: Adults age 18 and older who have primary sclerosing cholangitis. Design: Participants will be screened with a medical history, physical exam, a... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Oral Cannabidiol for Tobacco Cessation
NCT05445804
Recruiting
Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/07/2025
Locations: Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Tobacco Use, Tobacco Smoking, Tobacco Dependence, Tobacco Use Disorder, Tobacco Use Cessation
Register for Updates
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774
Recruiting
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Valkyrie Clinical Trials, Los Angeles, California +190 locations
Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Register for Updates
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
NCT06439836
Recruiting
This phase I trial tests the safety, side effects, best dose, and effectiveness of emavusertib (CA-4948) in combination with pembrolizumab in treating patients with urothelial cancer that has spread from where it first started to other places in the body (metastatic) and that has a resistance to PD-1/PD-L1 immune checkpoint inhibitors. CA-4948, a kinase inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California +1 locations
Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Register for Updates
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
NCT06690281
Recruiting
Background: Gastrointestinal (GI) cancer affects the organs (such as the stomach, large and small intestine, pancreas, colon, liver, and biliary system) of the digestive tract. In some participants who have had surgery for GI cancer, blood tests show that the cancer has spread despite being unable to be identified by scans. Certain gene mutations (changes) in GI cancer (such as KRAS or TP53) can be targeted by T cells, a type of immune cell, in individuals with specific HLA types (genes that he... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
05/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma, Duodenal Cancer, Colorectal Cancer, Small Bowel Cancer, Metastatic Cancers
Register for Updates
Environment and Alcohol: A Pilot Study
NCT06860607
Recruiting
Background: Alcohol use disorder (AUD) is a chronic disease that causes more than 140,000 US deaths each year. AUD treatment often includes therapy and medication. Some people with AUD may also benefit from behavioral and lifestyle changes. Objective: To evaluate the effects of different activities and environments on drinking behaviors and mental health in people with AUD. Eligibility: People aged 21 years and older with AUD. Design: Participants will have up to 10 study visits in Baltim... Read More
Gender:
ALL
Ages:
Between 21 years and 100 years
Trial Updated:
05/07/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Alcohol Use Disorder
Register for Updates
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375
Recruiting
Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +12 locations
Conditions: Colonic Neoplasms
Register for Updates
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04895241
Recruiting
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: -... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Tilda Research Birmingham, Homewood, Alabama +168 locations
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
NCT05470491
Recruiting
Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a standard reason to need transplant. Objective: This study is being done to see if a new combination of drugs (cyclophosphamide, maraviroc, and bortezomib) is both safe and effective at protecting against graft-versus-host disease after bone marrow transplant. The study... Read More
Gender:
ALL
Ages:
Between 12 years and 120 years
Trial Updated:
05/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: HIV, Hematologic Malignancies
Register for Updates
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
NCT06160284
Recruiting
This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET scans with the \[11C\]-UCB-J radiotracer while inpatient.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
05/07/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Opioid Use Disorder
Register for Updates
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
NCT06442761
Recruiting
This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. PRIMARY OBJECTIVE * To characterize the safety and tolerability of motixafortide in participants with SCD as determined by the incidence of adverse events (AEs). SECONDARY OBJECTIVES * To characterize the efficacy of a s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Register for Updates